INO

1.7653.22%
JE

Jacqueline E. Shea

CEO, President & Director

Dr. Jacqueline E. Shea, Ph.D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Operating Officer at Inovio Pharmaceuticals, Inc. since March 25, 2019 until May 10, 2022. She joined Inovio Pharmaceuticals, Inc. in March 2019. Dr. Shea is an experienced life sciences senior executive with an extensive track record of leadership, strategy development, operational management, product development and international corporate development achievements. She served as Chief Executive Officer from August 2015 to December 2018 and Chief Operating Officer from April 2014 to August 2015 of Aeras, the leading not-for-profit organization dedicated to developing new tuberculosis vaccines. At Inovio, Dr. Shea is responsible for Inovio's manufacturing, commercial, business development, and alliance management operations as well as serving as a key Member of the executive team along with CFO and CSO in formulating and implementing overall corporate strategy. Prior to her role at Aeras, Dr. Shea held top management positions at two biotechnology companies: Emergent Product Development UK (part of Emergent BioSolutions) and Microscience Ltd; and was General Manager of The Oxford-Emergent Tuberculosis Consortium, a global health joint venture formed between Oxford University and Emergent BioSolutions from 2008 to 2013. Dr. Shea previously served as Vice President of Business Development, Europe for Emergent BioSolutions Inc. from May 2013 to March 2014, having previously served as Senior Director of Business Development for Emergent BioSolutions from 2005 to 2008. She started her career as a post-doctoral researcher at Imperial College, London, where she contributed to the development of signature-tagged mutagenesis which received a Prix Galien commendation for excellence in innovative research. She is a molecular biologist and cell cycle geneticist. She has been named as an inventor on more than 20 patents, has authored numerous publications, served on multiple advisory boards and serves on the Board of Trustees for the Sabin Vaccine Institute. She received her PhD from the National Institute for Medical Research and a BSC Hons. in Applied Biology with First Class Honors from University of Bath, U.K.

Positions